Takeda Pharmaceutical's Q1 Earnings: A Closer Look at the Japanese Giant's Financial Performance

Takeda Pharmaceutical is set to announce its quarterly earnings on July 30, with analysts estimating an EPS of $0.47. The company's past performance has seen a mix of positive and negative price changes. Takeda Pharmaceutical's stock has risen 3.6% over the last 52-week period. Long-term shareholders are likely bullish ahead of this earnings release.

Takeda Pharmaceutical is set to announce its quarterly earnings on July 30, with analysts estimating an earnings per share (EPS) of $0.47 [1]. The company's past performance has been mixed, with both positive and negative price changes. Over the last 52-week period, Takeda Pharmaceutical's stock has risen 3.6%, indicating a generally positive trend [2].

Analyst Estimates and Market Expectations
Analysts are anticipating that Takeda Pharmaceutical will report an EPS of $0.47, which is crucial for investors to gauge the company's financial health. The market is hopeful that Takeda Pharmaceutical will surpass these estimates and provide upbeat guidance for the next quarter [1].

Historical Performance
Takeda Pharmaceutical's historical earnings and stock price changes provide insight into its financial trajectory. Here's a brief overview:

- Q4 2024: EPS Estimate $0.57, Actual $0.16, Price Change +1.0%
- Q3 2024: EPS Estimate $0.57, Actual $0.44, Price Change -2.0%
- Q2 2024: EPS Estimate $0.57, Actual $0.45, Price Change 0.0%
- Q1 2024: EPS Estimate $0.57, Actual $0.56, Price Change -0.0%

These figures suggest that while there have been fluctuations, the company has shown resilience in its earnings performance [1].

Market Performance
As of July 28, 2025, Takeda Pharmaceutical's stock was trading at $14.31, with a 52-week range of $12.80 to $15.53 [2]. The stock has experienced a decline in revenue and net profit over the past four quarters, which has contributed to a decrease in the stock's price. However, the long-term shareholders are likely bullish going into this earnings release due to the overall positive trend in the stock's performance [2].

Analyst Recommendations
Analysts are generally optimistic about Takeda Pharmaceutical's stock. Based on 23 analysts, 52% have a 'Buy' rating, 47% have a 'Hold' rating, and 0% have a 'Sell' rating. The average price target is $16.84, indicating a potential upside of 17.5% compared to the current price of $14.33 [2].

Conclusion
Takeda Pharmaceutical's upcoming quarterly earnings announcement on July 30 is a significant event for investors. With analysts estimating an EPS of $0.47 and the stock showing a positive trend over the last 52 weeks, investors are looking forward to the release for potential upbeat guidance and a potential price increase. The company's historical performance and analyst recommendations suggest a cautious optimism ahead of the earnings release.

References:
[1] https://www.benzinga.com/insights/earnings/25/07/46693078/insights-ahead-takeda-pharmaceuticals-quarterly-earnings
[2] https://www.indmoney.com/us-stocks/takeda-pharmaceutical-company-limited-share-price-tak